Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1251 - 1258 of 1258

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1401 - 1425 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
edaravone	sr0573-radicava-clinical-review-report.pdf sr0573-radicava-pharmacoeconomic-review-report.pdf sr0573_radicava-patient-input.pdf sr0573-radicava-cdec-rec-march-29-2019.pdf	Apr 25, 2019	Reimbursement Review		Complete	SR0573-000
Lenvima for Renal Cell Carcinoma – Details	pcodr_profund_lenvatinib_lenvima_rcc_10140.pdf 10140LenvatinibRCC_FnRec_approvedbyChair_Post_04Jan2019_final.pdf 10140LenvatinibRCC_fnCGR_REDACT_Post_04Jan2019_final.pdf 10140LenvatinibRCC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf pcodr_lenvatinib_lenvima_rcc_in_rec.pdf 10140_Lenvatinib_RCC_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf 10140LenvatinibRCC_SubmitterFeedback_2018-11-29_updated_Post_04Jan2019_final.pdf 10140LenvatinibRCC_PatientGroupFeedback_KCC_2018-11-15_Post_04Jan2019_final.pdf 10140LenvatinibRCC_ClinicianFeedback_Combined_Post_04Jan2019_final_Redacted.pdf 10140LenvatinibRCC_COI_KCC_2018-06-22_Post_04Jan2019_draft_Redacted.pdf 10140LenvatinibRCC_Combined_Clinician COIs_Post_04Jan2019_final.pdf	Apr 25, 2019	Reimbursement Review		Complete	PC0140 -000
Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1092 Buprenorphine for OUD Final.pdf	Apr 24, 2019	Health Technology Review	Summary with Critical Appraisal	Completed	RC1092-000
Blincyto for Philadelphia Chromosome positive B-cell precursor Acute Lymphoblastic Leukemia – Details	pcodr_profung_10146_blinatumomab_blincyto-all.pdf 10146BlinatumomabPh+ALL_FnCGR_04April2019_REDACT_POST_final.pdf 10146BlinatumomabPh+ALL_FnRec_04Apr2019_REDACT_post_final.pdf 10146BlinatumomabPh+ALL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf 10146_BlinatumomabPh+ALL_InRec_AprovedbyChair_REDACT_31Jan2019_final.pdf 10146Blinatumomab_Ph+ALL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf 10146BlinatumomabPh+ALL_SubmitterFeedback_2019-02-19_Post_04Apr2019_final.pdf 10146BlinatumomabPh+ALL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf 10146BlinatumomabPh+ALL_PatientGroupCOI_LLSC_2018-09-14_final.pdf 10146BlinatumomabPh+ALL_ClinicianInputCOI_Combined_04Apr2019_post_final.pdf	Apr 22, 2019	Reimbursement Review		Complete	PC0146-000
Folotyn for Peripheral T-Cell Lymphoma	pcodr_provfund_10138_pralatrexate_folotyn.pdf 10138PralatrexatePTCL_fnRec__04Apr2019_NOREDACT_post_final2.pdf 10138PralatrexatePTCL_fnCGR_NOREDACT_POST04Apr2019_final.pdf 10138PralatrexatePTCL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf 10138PralatrexatePTCL_InRec_31Jan2019_approvedbyChair_final.pdf 10138Pralatrexate_PTCL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_SubmitterFeedback_2019-02-14_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_PatientFeedback_LC_2019-02-14_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_PatientCOI_LC_2018-06-15_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_ClinicianCOI_Combined_Post_final.pdf	Apr 22, 2019	Reimbursement Review		Complete	PC0138-000
crisaborole	SR0570-Eucrisa-cdec-rec-april-2-2019.pdf sr0570-eucrisa-clinical-report.pdf sr0570-eucrisa-pharmacoeconomic-report.pdf SR0570-eucrisa-patient-input.pdf	Apr 18, 2019	Reimbursement Review		Complete	SR0570-000
Nusinersen	sr0576-spinraza-resubmission-clinical-report.pdf sr0576-spinraza-resubmission-pharmacoeconomic-report.pdf sr0576-spinraza-patient-input.pdf SR0576-Spinraza-Resubmission-Mar-1-19.pdf	Apr 18, 2019	Reimbursement Review		Complete	SR0576-000
fluticasone propionate / salmeterol xinafoate	SR0540 Arbesda RespiClick - CDEC Final Recommendation for Posting December 21, 2018.pdf sr0540-arbesda-respiclick_combined-report.pdf sr0540_arbesda-respiclick_PI_submissions.pdf	Apr 18, 2019	Reimbursement Review		Complete	SR0540-000
Buprenorphine hydrochloride	SR0550_Probuphine_Aug_24_18.pdf SR0550_Probuphine_CL_Report.pdf SR0550_Probuphine_PE_Report.pdf	Apr 18, 2019	Reimbursement Review		Complete	SR0550-000
Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review	Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review	Apr 18, 2019	Health Technology Review	Summary with Critical Appraisal	Completed	RC1099-000
Esketamine for Treatment-Resistant Depression		Apr 17, 2019	Horizon Scan			EH0075-000
CADTH Pharmaceutical Reviews Update — Issue 7		Apr 17, 2019	Reimbursement Review	Pharmaceutical Review Update
Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details	pcodr_profund_enzalutamide_xtandi_non-mcrpc_10149.pdf 10149Enzalutamidenm-CRPC_FnRec_EarlyConv_2019-03-26-v4_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_fnCGR_EC_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_fnEGR_EC_NOREDACT-ABBREV_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_InRec_approvedbyChair_NOREDACT_Post_07Mar2019_final.pdf 10149Enzalutamide_nmCRPC_PAGFeedbackSummary_FINAL_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_SubmitterFeedback_2019-03-21_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_ClinicianFeedback_CCO_2019-03-21_Post_26Mar2019_final.pdf 10149Enzalutamide-CRPC_COI_CCSN_Post_26Mar2019_final_Redacted.pdf 10149EnzalutamidenmCRPC_Combined_Clinician_COI_Post_26Mar2019_final.pdf	Apr 10, 2019	Reimbursement Review		Complete	PC0149-000
Unituxin for Neuroblastoma – Details	pcodr-provfund-10154-dinutuximab-unituxin-neuroblastoma.pdf 10154DinutuximabNeuroblastoma_fnRec_EC_ApprovedbyChair_2019-03-26_Post_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_fnCGR_ECPost_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_inRec_approvedbyChair_05Mar2019_Post_07Mar2019_final.pdf 10154Dinutuximab_Neuroblastoma_PAGFeedback_FINAL_Post_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_ClinicianFeedback_POGO_2019-03-21_Post_26Mar2019_final.pdf 10154Dinutuximab_Neuroblastoma_COI_Ac2orn_2018-10-15_Post_26Mar2019_final_Redacted.pdf 10154Dinutuximab_NeuroblastomaCombined_Clinician COI_Post_26Mar2019_final.pdf	Apr 10, 2019	Reimbursement Review		Complete	PC0154-000
CADTH Pharmaceutical Reviews Update — Issue 6		Mar 28, 2019	Reimbursement Review	Pharmaceutical Review Update
Horizon Scan Roundup — 2018		Mar 27, 2019	Horizon Scan			ER0007-000
cyclosporine		Mar 22, 2019	Reimbursement Review		Withdrawn	SR0518-000
Opdivo for Melanoma Adjuvant Therapy – Details	pcodr_provfund_10147_nivolumab_opdivo.pdf 10147NivolumabMelanoma(Adjuvant)_FnRec_ChairApproved_Post_07Mar2019_Final.pdf 10147NivolumabMelanoma(Adjuvant)_fnCGR_NOREDACT_POST07Mar2019_Final.pdf 10147NivolumabMAT_FnEGR_NOREDACT-ABBREV_POST07Mar2019_Final.pdf 10147NivolumabMelanoma(Adjuvant)_inRec_2019-01-03_ChairApproved_Post_04Jan2019_final.pdf 10147_Nivolumab_MAT_PAGFeedbackSummary_FINAL_Post_07Mar2019_Final.pdf 10147NivolumabMAT_SubmitterFeedback_2019-01-16_Post_07Mar2019_Final.pdf 10147NivolumabMAT_PatientFeedback_MNC_2019-01-17_Post_07Mar2019_Final.pdf 10147NivolumabMAT_ClinicianFeedback_CCO_2019-01-16_Post_07Mar2019_Final.pdf 10147NivolumabMAT_Patient_Combined_COIs_Post_07Mar2019_final.pdf 10147NivolumabMAT_Clinician_Combined_COI_Post_07Mar2019_final.pdf	Mar 22, 2019	Reimbursement Review		Complete	PC0147-000
Adcetris for Hodgkin Lymphoma Resubmission – Details	pcodr_profund_10145_brentuximab_adcetris_hl_resub.pdf 10145BrentuximabHL_FnRec_approvedbyChair_Post_07Mar2019_final.pdf 10145BrentuximabHL_fnCGR_NOREDACT_Post_07Mar2019_final.pdf 10145BrentuximabHL_FnEGR_NOREDACT-ABBREV_Post_07Mar2019_final.pdf 10145BrentuximabHL_InRec_approvedbyChair_Post_04Jan2019_final.pdf 10145BrentuximabHLResubmission_PAGFeedbackSummary_FINAL_post_07Mar2019_final.pdf 10145BrentuximabHL_SubmitterFeedback_2019-01-18_Post_07Mar2019_final.pdf 10145BrentuximabHL_PatientGroupFeedback_LC_2019-01-18_Post_07Mar2019_final.pdf 10145BrentuximabHL_Combined-ClinicianFeedback_Post_07Mar2019_final.pdf 10145BrentuximabHL_PatientInputCOI_LC_REVISED2018102_Post_07Mar2019_REDACTED_final.pdf 10145BrentuximabHL_ClinicianInputCOI_Combined_2018-09-10_ForPosting_REDACTED_final.pdf	Mar 22, 2019	Reimbursement Review		Complete	PC0145-000
Health Technology Reassessment: An Overview of Canadian and International Processes		Mar 22, 2019	Health Technology Review			ES0334-000
Environmental Scan on Health Technology Reassessment Processes		Mar 22, 2019	Health Technology Review			ES0334-000
Cabometyx for Renal Cell Carcinoma Resubmission – Details	pcodr_profund_10163_cabozantinib_cabometix.pdf 10163CabozantinibRCCResub_FnRec_2019-02-20_ApprovedByChair_Post_20Feb2019_final.pdf 10163CabozantinibRCCResub_fnCGR_EC_NOREDACT_Post_21Feb2019_final.pdf 10163CabozantinibRCCResub_fnEGR_EC_NOREDACT-ABBREV_Post_20Feb2019_final.pdf 10163CabozantinibResubmissionRCC_inRec_2019-01-30_v10_ChairApproved_Post_31Jan2019_final.pdf 10163CabozantinibRCCResub_PAGFeedbackSummary_FINAL_2019-02-08_Post_20Feb2019_final.pdf 10163CabozantinibRCCResub_SubmitterFeedback_2019-02-14_Post_20Feb2019_final.pdf 10163CabozantinibRCCResub_ClinicianFeedback_CCO_2019-02-11_Post_20Feb2019_final.pdf 10163CabozantinibRCCResub_COI_KCC_2017-10-23_Post_20Feb2019_final_Redacted.pdf 10163CabozantinibRCCResub_Clinician_Combined COI_Post_20Feb2019_final.pdf	Mar 7, 2019	Reimbursement Review		Complete	PC0163-000
ataluren		Mar 5, 2019	Reimbursement Review		Cancelled	SR0607-000
Health Technology Update — Issue 23		Mar 4, 2019	Horizon Scan	Health Technology Update	Completed	EN0013-000
Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes		Feb 27, 2019	Health Technology Review	Environmental Scan	Completed	ES0337-000